Janux Therapeutics, Inc. (JANX)
|Net Income (ttm)||-7.66M|
|Trading Day||June 23|
|Day's Range||21.44 - 23.40|
|52-Week Range||16.32 - 37.99|
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase...
LA JOLLA, Calif.--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previo...
Janux Therapeutics, Inc. (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the pricing of its initial public offering of 11,400,000 shares of its comm...
Janux Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on our proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Our initial focus is on developing a novel class of T cell engagers (TCEs), an emerging class of immunotherapies that bridge a tumor cell and a T cell, to activate and redirect T cells to attack and eliminate tumors, and our lead product candidates are designed to target clinically validated drug targets. We are d... [Read more...]
|IPO Date |
Jun 11, 2021
David Campbell, Ph.D.
|Stock Exchange |
|Ticker Symbol |